白介素17、白介素33在颅内动脉粥样硬化斑块中的作用及在缺血性卒中的展望

doi:10.3969/j.issn.1673-5765.2017.10.019

摘要/Abstract

摘要：

颅内血管粥样硬化会导致脑血管病，在颅内血管斑块的形成过程中以及缺血后的脑损伤中，炎症反应都起到至关重要的作用。近年来研究证实，白介素-17（interleukin-17，IL-17）与受体结合激活通路促进动脉粥样硬化斑块的形成，并且加重脑缺血组织的损伤，而白介素-33（interleukin-33， IL-33）在缺血性卒中通过I L-33/ST2L信号通路参与了颅内动脉硬化斑块的形成过程，且被证实是一种保护因素。本文总结了在颅内大血管硬化斑块的形成过程中IL-17与IL-33之间的相互影响。其各自水平的高低可反映疾病的严重程度，提出其对缺血性卒中的临床治疗及预示预后转归具有重要意义。

文章导读： 本文首次从不同方面揭示了白介素-17和白介素-33在颅内大血管动脉粥样硬化中的作用，从而证实其在缺血性卒中病变发展过程中可能扮演的积极或者消极角色，这为改善卒中预后和治疗提供了新的研究思路。

关键词: 白介素17; 白介素33; 颅内动脉粥样硬化斑块; 缺血性卒中

Abstract:

Cerebral vascular disease can be caused by intracranial atherosclerosis, during the formation of intracranial vascular plaques and post ischemic brain injury, and inflammation plays a crucial role. In recent years, studies have confirmed that interleukin 17 (IL-17) and the receptor activation pathway could promote the formation of atherosclerotic plaque and aggravate cerebral ischemia injury, and interleukin-33 (IL-33) got involved in the intracranial atherosclerotic plaques of ischemic stroke through IL-33/ST2L signaling pathway, which might be proved as a protective factor in atherosclerosis. This paper summarized mutual influence between IL-17 and IL-33 in the formation process of intracranial large artery atherosclerosis plaque. The level of their respective could reflect the severity of disease, which was of great significance to the clinical treatment and prognosis of ischemic stroke.

Key words: Interleukin-17; Interleukin-33; Intracranial atherosclerosis plaque; Ischemic stroke

杨诗琪，李国忠，钟镝，陈洪苹，刘天怡，赵庆龙，徐辰. 白介素17、白介素33在颅内动脉粥样硬化斑块中的作用及在缺血性卒中的展望[J]. 中国卒中杂志, 2017, 12(10): 968-971.

YANG Shi-Qi, LI Guo-Zhong, ZHONG Di, CHEN Hong-Ping, LIU Tian-Yi,ZHAO Qing-Long, XU Chen. The Function of Interleukin-17 and Interleukin-33 in Intracranial Atherosclerotic Plaques and Its Prospect in Ischemic Stroke[J]. Chinese Journal of Stroke, 2017, 12(10): 968-971.

参考文献

[1] ROQUILLY A，LEJUS C，ASEHNOUNE K. Brain

injury，immunity and infections[J]. Ann Fr Anesth

Reanim，2012，31（6）：e97-100.

[2] SAVER J L. Cryptogenic Stroke[J]. N Engl J Med，

2016，374（21）：2065-2074.

[3] SHIMIZU K，SHIMOMURA K，TOKUYAMA Y，

et al. Association between inflammatory biomarkers

and progression of intracranial large artery stenosis

after ischemic stroke[J]. J Stroke Cerebrovasc Dis，

2013，22（3）：211-217.

[4] SHICHITA T，AGO T，KAMOUCHI M，et al.

Novel therapeutic strategies targeting innate immune

responses and early inflammation after stroke[J]. J

Neurochem，2012，123（Suppl 2）：29-38.

[5] LIBBY P，OKAMOTO Y，ROCHA V Z，et al.

Inflammation in atherosclerosis[J]. Circ J，2010，74

（2）：213-220.

[6] GAFFEN S L. Recent advances in the IL-17 cytokine

family[J]. Curr Opin Immunol，2011，23（5）：613-

619.

[7] MILLER A M，XU D，ASQUITH D L，et al. IL-33

reduces the development of atherosclerosis[J]. J Exp

Med，2008，205（2）：339-346.

[8] MARZULLO A，AMBROSI F，INCHINGOLO

M，et al. ST2L transmembrane receptor expression：

an immunochemical study on endarterectomy

samples[J]. PLoS One，2016，11（5）：e0156315.

[9] TALEB S，TEDGUI A，MALLAT Z. IL-17 and

Th17 cells in atherosclerosis：subtle and contextual

roles[J]. Arterioscler Thromb Vasc Biol，2015，35

（2）：258-264.

[10] XU S，CAO X. Interleukin-17 and its expanding

biological functions[J]. Cell Mol Immunol，2010，7

（3）：164-174.

[11] IWAKURA Y，ISHIGAME H，SAIJO S，et al.

Functional specialization of interleukin-17 family

members[J]. Immunity，2011，34（2）：149-162.

[12] MADDUR M S，MIOSSEC P，KAVERI S V，et al.Th17 cells：biology，pathogenesis of autoimmune and

inflammatory diseases，and therapeutic strategies[J].

Am J Pathol，2012，181（1）：8-18.

[13] CHEN J，LIAO M Y，GAO X L，et al. IL-17A

induces pro-inflammatory cytokines production in

macrophages via MAP Kinases，NF-κB and AP-1[J].

Cell Physiol Biochem，2013，32（5）：1265-1274.

[14] CHENG X，TALEB S，WANG J，et al. Inhibition of

IL-17A in atherosclerosis[J]. Atherosclerosis，2011，

215（2）：471-474.

[15] NGUYEN H，CHIASSON V L，CHATTERJEE

P，et al. Interleukin-17 causes Rho-kinase-mediated

endothelial dysfunction and hypertension[J].

Cardiovasc Res，2013，97（4）：696-704.

[16] TAKAHASHI H，NUMASAKI M，LOTZE M T，et

al. Interleukin-17 enhances bFGF-，HGF- and VEGFinduced

growth of vascular endothelial cells[J].

Immunol Lett，2005，98（2）：189-193.

[17] MA T，GAO Q，ZHU F，et al. Th17 cells and IL-17

are involved in the disruption of vulnerable plaques

triggered by short-term combination stimulation

in apolipoprotein E-knockout mice[J]. Cell Mol

Immunol，2013，10（4）：338-348.

[18] LI H L，KOSTULAS N，HUANG Y M，et al. Il-

17 and IFN-gamma mRNA expression is increased

in the brain and systemically after permanent

middle cerebral artery occlusion in the rat[J]. J

Neuroimmunol，2001，116（1）：5-14.

[19] LUO Y，ZHOU Y，XIAO W，et al. Interleukin-33

ameliorates ischemic brain injury in experimental

stroke through promoting Th2 response and

suppressing Th17 response[J]. Brain Res，2015，1597：

86-94.

[20] KUNES P，MANDAK J，HOLUBCOVA Z，et

al. Actual position of interleukin （IL）-33 in

atherosclerosis and heart failure：Great Expectations

or En attendant Godot?[J]. Perfusion，2015，30（5）：

356-374.

[21] MCLAREN J E，MICHAEL D R，SALTER R C，et

al. IL-33 reduces macrophage foam cell formation[J].

J Immunol，2010，185（2）：1222-1229.